Recurrence Rates of Incompletely Excised Primary Basal Cell Carcinoma Treated With Mohs Micrographic Surgery and Radiotherapy Authors: Georgia De'Ambrosis, Brian De'Ambrosis, Perry Wilson, Alexander Coe Published: 2026 ABSTRACT ABSTRACTBackground/ObjectivesIncompletely excised primary basal cell carcinoma (pBCC) is a frequently encountered scenario in clinical practice, yet the significance of the phenomenon is not well described in current literature. Re‐excision is recommended for high‐risk incompletely excised pBCCs, but recurrence rates post re‐excision of pBCCs with Mohs micrographic surgery (MMS) are not currently well documented.MethodA retrospective cohort study was undertaken, identifying patients who had undergone re‐excision with MMS for pBCC prior to June 2015 from the private practices of two MMS proceduralist dermatologists' practices in Queensland, Australia. Cases required a minimum follow up of 5 years post‐definitive treatment.Results141 patients were identified, with 104 ultimately being included. 31 patients did not respond, and 6 formally withdrew. 104 incompletely excised pBCCs re‐excised with MMS, with some cases receiving adjuvant post‐operative radiotherapy (PORT), experienced no recurrence over an average follow up period of 9.2 years. 93 (92.1%) of the 104 cases consisted of an aggressive BCC subtype, and 54 (51.9%) of the cases were in a high‐risk anatomical location. Perineural invasion was present in 12 (11.5%) cases, and 6 (5.7%) of the cases received PORT.ConclusionMMS may be an effective treatment option for the management of incompletely excised pBCC in immunocompetent patients. For high‐risk cases, PORT is an effective adjuvant therapy in combination with MMS. Future prospective studies with greater participant numbers and the inclusion of recurrent BCCs, as well as BCCs initially treated with non‐surgical methods, may provide further insights into the role of MMS in these clinical contexts.Keywords: basal cell carcinoma, Mohs surgery, surgical margins Introduction Basal cell carcinomas (BCCs) are the most commonly occurring keratinocyte skin cancer [1], with incidence increasing globally [2]. BCCs most frequently occur in patients over the age of 50, with sun exposure being the most substantial risk factor associated with development of the tumour [2]. In a Cochrane review focusing on BCC interventions by Thomson et al., the conclusion was made that surgical management is associated with the lowest level of BCC recurrence [3]. The authors also noted that Mohs micrographic surgery (MMS) may be associated with lower rates of recurrence for high‐risk primary facial BCCs when compared to surgical excision at 5 years [3]. Considering these findings, the assumption can be made that MMS would be an effective treatment modality for primary BCCs (pBCCs) incompletely excised. The Cancer Council Australia's clinical practice guidelines for the management of keratinocyte cancers recommend that incompletely excised BCCs should have treatment selected on a case‐by‐case basis [4], but that BCCs with high‐risk features, or that occur in high‐risk sites, should be re‐excised [4]. In their prospective study analysing residual tumour rates of BCC re‐excised with MMS, Palmer and Wilson recommended that incompletely excised BCCs be immediately re‐excised, and that the watch and wait philosophy for these tumours is not an appropriate option [5]. The significance of incomplete excision on pBCC recurrence risk has largely not been explored to date. Incompletely excised lesions are a common clinical scenario, with incidence estimated between 1.9% and 16% [5], and occurring 2.5 times more often on the nose or ear [6]. Incompletely excised BCCs are thought to exhibit more aggressive behaviours, which include challenges in assessing clinical margins [5], fibrosis leading to deeper rather than superficial extension, lesions more likely to exhibit aggressive histopathological subtype at initial treatment [5, 7] and potentially exhibiting a more extensive subclinical spread [8]. The primary objective of this study was to analyse the recurrence rates of incompletely excised pBCC definitively managed by re‐excision with MMS. To the authors' knowledge, this is the only current retrospective cohort study to specifically examine the recurrence of incompletely excised pBCC post re‐excision with MMS. Materials and Methods Study Design A retrospective cohort of patients with an incompletely excised pBCC was established based on whether they had undergone MMS for definitive treatment. Tumour recurrence following definitive surgery for incompletely excised pBCC was the primary outcome of the study, with a minimum follow up of 5 years post‐definitive treatment. Characteristics of each tumour were recorded to allow analysis regarding possible predictors of future recurrence. Setting This Queensland‐based study identified patients from the private practices of two MMS proceduralist dermatologists who had undergone a re‐excision procedure for pBCC prior to June 2015. These patients were then invited to participate in a follow up questionnaire with respect to tumour recurrence in the subsequent years post‐surgery. Participants Patients with an incompletely excised pBCC were identified as participants based on a search of histopathology reports at each private practice. A minimum follow‐up period of 5 years was required for participant inclusion. Tumours were excluded if they were considered recurrent in nature or previously treated by non‐surgical methods such as cryotherapy. Consent to participate in the study was obtained via written correspondence sent to each participant. Consenting participants were contacted via telephone to answer a series of questions. The date of the most recent skin examination and the practitioner type (dermatologist, surgeon or general practitioner) performing the check was noted. In the event of possible recurrence, the patient's doctor was to be contacted and the nature of recurrence, if applicable, was to be discussed. Variables and Data Sources/Measurement Incompletely excised pBCC was defined as a non‐recurrent BCC previously treated with surgical excision with curative intent with involved margin/s. Lesions were excluded if previous treatments included non‐excision modalities, such as cryotherapy, topical imiquimod or curettage with cautery. Variables of interest were collected from medical records, telephone conversation and discussion with participants, which included age at diagnosis, history of immunosuppression, date of initial treatments, tumour location, number of MMS stages to achieve tumour clearance, BCC subtype, presence of perineural invasion (PNI), use of radiotherapy, date of last follow up with the treating dermatologist, details of most recent skin examination, duration of follow up and details of recurrence (if applicable). The collection of data was performed via telephone conversation based on a transcript and performed by the same researcher for all participants. Bias Potential sources of bias included non‐responder, recall and volunteer bias. Loss‐to‐follow up was noted within the cohort. Participant telephone follow‐up does rely on participant memory of past exposures, which was minimised by communication with subsequent treating doctor in the event of possible recurrence. Patients volunteering to be participants may have differed in their socio‐demography, behaviour and general health attitudes. Finally, the use of post‐operative radiotherapy had the potential to reduce the risk of recurrence following surgery. Quantitative Variables Variables studied included age at definitive treatment, immunosuppression status, duration between initial incomplete excision and re‐excision, along with the timing and nature of follow up. Results Participants 141 incompletely excised BCCs treated with MMS were initially identified on review of medical records at each practice. As outlined in Table 1, 37 participants were lost to follow up. Possible reasons included patient preference not to participate, death of the patient in the period following treatment, or the patient not receiving written communication with the postal address subsequently changing in the follow up period. TABLE 1Participant cohort sizes and loss to follow up.Treatment modalityMMSTotal # participants (initial)141Loss to follow up 37 total 31—no response 6—written advice received electing not to participate Total # participants at conclusion of study (minimum 60 months follow up)104 Participant cohort sizes and loss to follow up. 37 total 31—no response 6—written advice received electing not to participate Descriptive Data Table 2 outlines patient demographics. The mean age at time of MMS was 63.4 years. A male predominance was noted of 54.8%. No participants with missing data were included. Mean follow up time was 9.2 years. TABLE 2Patient and tumour characteristics for each eligible case included in the study.Mohs group n = 104 n (%)Age at definitive treatmentMean63.4SexFemale47 (45.2)Male57 (54.8)Immunosuppressed0 (0.0)Duration between initial excision and definitive treatmentMean (months)4.7 (3.5–8.3)Follow up typeDermatologist73 (70.2)Surgeon0 (0.0)GP31 (30.0)Duration of follow upMean (years)9.2 (8.1–11.1) Patient and tumour characteristics for each eligible case included in the study. Outcome Data No recurrences were noted over a mean follow up period of 9.2 years. Table 3 outlines tumour details including location, BCC subtype and high‐risk features. TABLE 3Tumour details and follow up.MMS n = 104 n (%)Lesion siteNose35 (32.7)Ear13 (12.1)Lip2 (1.2)Periocular4 (3.7)Non‐head & neck3 (2.8)High risk site (nose/ear/lip/periocular)54 (51.9)BCC subtype (individual lesions contained ≥ 1 subtype)Infiltrative48 (46.2)Morphoeic20 (19.2)Micronodular24 (23.1)Total number of high‐risk BCCs a 93 (92.1)Number of previous incomplete excisions184 (80.8)213 (12.5)36 (5.8)41 (1.0)Number of Mohs stages to achieve clearance160 (57.7)234 (32.7)35 (4.8)44 (3.8)51 (0.9)Presence of PNI12 (11.5)Post op XRT6 (5.7)Biopsy‐proven recurrence0 (0.0) a High‐risk subtypes in this study included infiltrative, morphoeic and/or micronodular BCCs. All remaining cases were low‐risk BCCs of either superficial and/or nodular subtype. No basosquamous cases were included. Tumour details and follow up. High‐risk subtypes in this study included infiltrative, morphoeic and/or micronodular BCCs. All remaining cases were low‐risk BCCs of either superficial and/or nodular subtype. No basosquamous cases were included. Discussion Of the 104 incompletely excised pBCCs included in this study, no tumours experienced recurrence post re‐excision with MMS over an average 9.2 year follow up. These findings are likely reflective of the combined effect of MMS, and in 6 (5.7%) cases with high‐risk features, adjuvant post‐operative radiotherapy (PORT). Whilst no cases within this study experienced recurrence, it cannot be entirely attributed to MMS alone, as cases that received PORT demonstrated higher risk features including infiltrative subtype, advanced age and greater incidences of PNI. It should also be noted that all patients in this study were immunocompetent, and that efficacy of MMS in the treatment of incompletely excised BCCs in immunosuppressed patients may differ. Overall, within this cohort of immunocompetent patients, MMS with selective use of PORT for high‐risk cases resulted in no recurrences across all 104 cases. Of note, of the 98 cases that were managed with MMS alone, no recurrences were observed, highlighting the effectiveness of MMS for re‐excision of incompletely excised pBCCs. In a meta‐analysis by Alsaif et al., the authors concluded that MMS is superior to standard surgical excision with respect to both primary and recurrent BCC of the head and neck [9]. However, recurrence rates for incompletely excised primary BCC were not reported [9]. Brown et al. note that both residual and recurrent BCC tumours have a greater risk of recurrence post MMS, with risk factors for recurrence including tumour duration prior to MMS, presence of aggressive BCC subtype and PNI on histology, previous recurrence and number of treatments [10]. It is important to highlight that no cases in our study experienced tumour recurrence, despite 92.1% of tumours being considered an aggressive subtype and 51.9% located in a high‐risk anatomical location. PNI was also present in 11.5% of cases. In a retrospective study by Jackson et al., they concluded that BCC with PNI is associated with a low risk of recurrence and has excellent prognosis when treated with adjuvant radiotherapy or MMS [11]. Armstrong et al. made similar conclusions, noting that whilst PNI is indicative of the potential aggressive nature of a BCC tumour, it does not influence recurrence rates in the context of adequate margin control and adjuvant radiotherapy [12]. Adams et al. also highlighted in their analysis of data from the Perineural Invasion Registry that surgery alone is an adequate treatment option for BCCs with incidental PNI of < 0.1 mm, noting that there were no tumour recurrences at 5 years within their study [13]. However, the authors did highlight that PNI presence does increase risk of local tumour occurrence [13], which was not demonstrated in our study. Morgan et al.'s study supports current literature that MMS is a protective feature when used for the management of BCCs and is associated with lower rates of local recurrence for these tumours [14]. PORT was used in 5.7% of cases. PORT is recommended for BCCs with gross perineural spread and is conditionally recommended in cases with close margins that cannot undergo further surgery, in the setting of recurrence with previous clear margin resection and in patients with locally advanced tumours involving bone or muscle [15]. Characteristics of lesions referred for PORT in our study included infiltrative subtype, older age and a higher incidence of PNI. None of these lesions experienced tumour recurrence. In contrast, a retrospective study by Kuiper et al. examined 1021 BCCs located on the head and neck treated with MMS, and found a recurrence rate of 6.9% in residual BCC cases subsequently managed with MMS [16]. The differences in outcomes between Kuiper et al.'s findings and this current study may be explained by the adjuvant PORT used for high‐risk cases, which may provide an additional element of protection against local recurrence. This difference in outcomes between these two studies may suggest that for high‐risk incompletely excised pBCCs, the combination of MMS and PORT could be considered as an effective multimodal treatment approach. Evidence of histological residual tumour on re‐excision occurs in approximately 50% of BCC tumours reported as incompletely excised [1]. Current literature also suggests that within a follow up period of 2–5 years, between 26% and 41% of incompletely excised BCCs experience recurrence, with the morphoeic subtype being most reportedly associated with recurrence [1, 17, 18]. Daviti et al.'s study on the management of incompletely excised BCCs further highlights the lower risk of recurrence associated with BCCs, with only 16.7% of their included BCC cases with positive clinical margins recurring clinically [17]. 40 patients in Davit et al.'s study did not undergo further treatment post initial surgery resulting in positive margins, and only 25% of these cases experienced recurrence [17]. Whilst there may be a lower associated risk of recurrence with incompletely excised pBCC, the tumours in our study were mainly of aggressive subtypes with other high risk features, and warranted re‐excision. Limitations This study has multiple limitations. Firstly, the general nature of a retrospective cohort study does not allow for randomisation. As a result, selection bias was a potential limiting factor in the overall findings. The inclusion of only primary tumours treated with previous surgery created a narrow focus for the project. Conclusions regarding the role of MMS in the setting of recurrent incompletely excised BCC or tumours treated initially with non‐surgical methods remain in question. Another limitation is the use of PORT in 6 (5.7%) of cases. These cases were not randomly allocated to PORT, but rather, were representative of some of the higher‐risk cases within this study cohort. As a result, this is a confounding factor that prevents attribution of the zero‐recurrence rate found in this study to MMS alone. Future studies should focus on separately reporting outcomes of incompletely excised pBCCs treated with MMS alone and MMS with adjuvant therapies such as PORT, which would allow for the impact of each modality to be specifically analysed. As previously noted, non‐responder, recall and volunteer bias were present to some extent. A 26% loss to follow‐up rate represents a significant limitation of this study. Patients who experienced negative outcomes, such as recurrence, may have been less likely to respond, potentially overestimating the favourable outcomes associated with MMS in this specific group. Additionally, patients who volunteered to participate may represent a more engaged population, further introducing volunteer bias. Five‐year follow up was considered a minimum duration, with van Loo et al. previously reporting 56% of recurrences for primary BCC occurring more than 5 years after initial treatment [19], with our study notably approaching 10 years of follow up. However, the possibility of recurrences occurring beyond the follow up period cannot be excluded. Small sample size also limits the statistical power of this study. Conclusion In summary, there were no tumour recurrences over an average follow up period of 9.2 years in incompletely excised pBCCs definitively managed with MMS, highlighting that MMS may be an effective treatment option in non‐immunocompromised patients. The combined use of adjuvant PORT in select high‐risk cases also likely contributed to the overall zero‐recurrence rate within this study cohort. A higher power prospective study with greater participant numbers and the inclusion of recurrent BCCs and BCCs initially treated with methods other than surgery may provide further insights into the significance of incompletely excised BCC, and the role of MMS in these clinical contexts. Funding The authors have nothing to report. Disclosure Declaration of use of AI: AI was not used in the production of this manuscript. Ethics Statement The study received approval from the University of Queensland Medicine, Institutional Human Research Low & Negligible Risk Ethics Subcommittee (Protocol No: 20190011810). Conflicts of Interest The authors declare no conflicts of interest. Acknowledgements Dr. B. De'Ambrosis, Dr. P. Wilson and Dr. A. Coe contributed to the design of the study. Dr. Coe is responsible for data analysis. All co‐authors contributed to the writing of the manuscript. All co‐authors provided important intellectual input and approved the final version of the manuscript. Open access publishing facilitated by Griffith University, as part of the Wiley ‐ Griffith University agreement via the Council of Australasian University Librarians. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.